About

L1 Therapeutics is developing precision therapies to slow cancer progression by suppressing LINE-1, which is an ancient virus-like element in the human genome that reactivates under stress. LINE-1 can help tumor cells to adapt and to progress to more advanced disease. Because it is mostly silent in healthy adult tissues, inhibitors of LINE-1 primarily target disease causing cells

In cancer, tumor cells can be under considerable stress, and that stress is increased further through treatment, which can overwhelm tumor cells. However, it also puts pressure on cells to resist treatment, and LINE-1 helps enable this

New technology enables us to now identify tumors in which LINE-1 activity may be treatable. We are focused on selected solid tumors that show genomic signs of active LINE-1 biology and do not have other drivers of genomic instability causing resistance

Team

L1 Therapeutics was founded by William Brandler, who trained in Human Genomics with a PhD from the University of Oxford and postdoctoral work at the University of California, San Diego. His background spans cancer genomics and computational biology, with over a decade of experience applying large‑scale genomic data to the study of disease biology in academic and industry settings

L1 Therapeutics works with scientific advisors including Alysson Muotri, Professor at UC San Diego, and RORR Consulting, whose CEO is Richard Ogden

Partnerships

L1 Therapeutics is advancing its therapeutic strategy with the intent to collaborate with pharmaceutical and diagnostics partners

Contact

For scientific, partnering, or investment inquiries:

Loading contact…